Ian David Postlethwaite
Plus aucun poste en cours
Historique de carrière de Ian David Postlethwaite
Anciens postes connus de Ian David Postlethwaite
Sociétés | Poste | Début | Fin |
---|---|---|---|
NETSCIENTIFIC PLC | Directeur/Membre du Conseil | 15/06/2016 | - |
Directeur Général | 30/04/2019 | 30/04/2020 | |
Directeur Financier/CFO | 13/06/2016 | 30/04/2020 | |
Secrétaire Général | 13/06/2016 | - | |
Shoreham Port Authority | Directeur/Membre du Conseil | - | 31/12/2016 |
ALLERGY THERAPEUTICS PLC | Directeur/Membre du Conseil | 23/11/2010 | 10/06/2016 |
Directeur Financier/CFO | 01/07/2004 | 10/06/2016 | |
Secrétaire Général | 01/10/2009 | 10/06/2016 | |
Ellerman Investments Ltd.
Ellerman Investments Ltd. Financial ConglomeratesFinance Ellerman Investments Ltd. provides financial services. The private company is based in London, UK. and has subsidiaries in United Kingdom. Ellerman Investments was founded in 1984. | Directeur Général | 01/01/1997 | 01/01/2002 |
PDS Operating Corp.
PDS Operating Corp. BiotechnologyHealth Technology PDS Operating Corp. operates as a biopharmaceutical company. It develops immunotherapies for cancer and infectious disease. The firm’s versamune is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The company was founded by Frank K. Bedu-Addo and Gregory L. Conn and is headquartered in Princeton, NJ. | Directeur/Membre du Conseil | - | - |
Glycotest, Inc.
Glycotest, Inc. Electronic Equipment/InstrumentsElectronic Technology Glycotest, Inc. develops diagnostic markers for liver disease diagnosis. It offers disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals. The company was founded in 2012 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - | - |
ProAxsis Ltd.
ProAxsis Ltd. Pharmaceuticals: MajorHealth Technology ProAxsis Ltd. manufactures and markets pharmaceutical products . It offers clinical research and research and development services. The company was founded by Lorraine Martin and Brian Walker in August 2013 and is headquartered in Belfast, the United Kingdom. | Directeur/Membre du Conseil | - | - |
Association of Friendly Societies Conference | President | - | - |
Formation de Ian David Postlethwaite
University of Aston | Undergraduate Degree |
Statistiques
Internationale
Royaume-Uni | 7 |
Etats-Unis | 3 |
2 |
Opérationnelle
Director/Board Member | 6 |
Director of Finance/CFO | 2 |
Corporate Secretary | 2 |
Sectorielle
Health Technology | 5 |
Finance | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
ALLERGY THERAPEUTICS PLC | Health Technology |
NETSCIENTIFIC PLC | Health Technology |
Entreprise privées | 6 |
---|---|
Ellerman Investments Ltd.
Ellerman Investments Ltd. Financial ConglomeratesFinance Ellerman Investments Ltd. provides financial services. The private company is based in London, UK. and has subsidiaries in United Kingdom. Ellerman Investments was founded in 1984. | Finance |
Association of Friendly Societies Conference | |
Shoreham Port Authority | Government |
ProAxsis Ltd.
ProAxsis Ltd. Pharmaceuticals: MajorHealth Technology ProAxsis Ltd. manufactures and markets pharmaceutical products . It offers clinical research and research and development services. The company was founded by Lorraine Martin and Brian Walker in August 2013 and is headquartered in Belfast, the United Kingdom. | Health Technology |
Glycotest, Inc.
Glycotest, Inc. Electronic Equipment/InstrumentsElectronic Technology Glycotest, Inc. develops diagnostic markers for liver disease diagnosis. It offers disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals. The company was founded in 2012 and is headquartered in New York, NY. | Electronic Technology |
PDS Operating Corp.
PDS Operating Corp. BiotechnologyHealth Technology PDS Operating Corp. operates as a biopharmaceutical company. It develops immunotherapies for cancer and infectious disease. The firm’s versamune is capable of potent activation of immune cells without the side effects of traditional vaccines, efficiently delivering disease related antigen targets to the immune system and promoting antigen processing to present antigen appropriately to generate both strong prophylactic and therapeutic immune responses to disease. The company was founded by Frank K. Bedu-Addo and Gregory L. Conn and is headquartered in Princeton, NJ. | Health Technology |
- Bourse
- Insiders
- Ian David Postlethwaite
- Expérience